Recent News

• 04.08.2025 - TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
• 04.07.2025 - TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
• 04.01.2025 - TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
• 03.11.2025 - TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
• 03.10.2025 - TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
• 02.19.2025 - TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference

Recent Filings

• 04.08.2025 - 425 Prospectuses and communications, business combinations
• 04.01.2025 - 8-K Current report
• 04.01.2025 - 425 Prospectuses and communications, business combinations
• 04.01.2025 - EX-99.1 EX-99.1
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.19.2025 - 3 Initial statement of beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 8-K Current report
• 03.18.2025 - EX-99.1 EX-99.1
• 03.12.2025 - EX-99.1 EX-99.1